Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999657 | Urologic Oncology: Seminars and Original Investigations | 2015 | 9 Pages |
Abstract
Long-term survival for patients with sRCC, even in clinically localized disease, is poor. Aggressive surveillance of those who have NED following nephrectomy is essential, and further prospective studies evaluating the benefit of adjuvant systemic therapies in this cohort are warranted.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Megan M. D.O., Christopher G. M.D., F.A.C.S., Nizar M. M.D., F.A.C.P., Rebecca S. M.S., Kara N. M.D., Eric M.D., Lance C. M.D., Zachary M.D., Pheroze M.D., Kanishka M.D., Louis L. M.D., Surena F. M.D., F.A.C.S., Jose A. M.D., F.A.C.S.,